奥翔药业(603229) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was RMB 205,113,465.95, representing a year-on-year increase of 42.45%[6] - Net profit attributable to shareholders of the listed company reached RMB 70,722,644.75, up 61.18% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 70,807,229.08, reflecting a 63.54% increase year-on-year[6] - Basic earnings per share for the period was RMB 0.25, an increase of 66.67%[6] - Total operating revenue for Q1 2022 reached ¥205,113,465.95, a 42.3% increase from ¥143,993,120.12 in Q1 2021[28] - Net profit for Q1 2022 was ¥70,722,644.75, compared to ¥43,878,486.62 in Q1 2021, reflecting a 60.9% growth[28] - Earnings per share for Q1 2022 were ¥0.25, an increase from ¥0.15 in Q1 2021[31] - The total comprehensive income for Q1 2022 was ¥70,711,987.61, compared to ¥42,881,285.95 in Q1 2021, reflecting a significant increase[31] Assets and Liabilities - Total assets at the end of the reporting period were RMB 1,941,315,156.97, a 5.54% increase from the end of the previous year[9] - Shareholders' equity attributable to the listed company was RMB 1,325,527,095.36, up 5.64% from the previous year-end[9] - The company's total current assets amounted to approximately CNY 1,082.31 million, an increase from CNY 1,020.58 million as of December 31, 2021, representing a growth of about 6.06%[18] - The company's total assets reached CNY 1,941.32 million, up from CNY 1,839.46 million, indicating a growth of about 5.54%[22] - Non-current assets totaled CNY 859.01 million, an increase from CNY 818.87 million, representing a growth of approximately 4.91%[22] - The company's total liabilities increased to CNY 1,082.31 million, up from CNY 1,020.58 million, indicating a growth of about 6.06%[22] - Total liabilities as of the end of the reporting period were ¥615,788,061.61, up from ¥584,640,297.04, marking a 5.2% increase[28] Cash Flow - The net cash flow from operating activities was negative RMB 2,327,836.82, a decrease of 22.28% year-on-year[6] - Cash flow from operating activities in Q1 2022 was ¥117,924,757.45, compared to ¥90,876,083.57 in Q1 2021, indicating a 29.8% increase[32] - Net cash flow from operating activities was -$2,327,836.82, compared to -$1,903,712.91 in the previous period, indicating a decline in operational cash flow[36] - Total cash inflow from investment activities was $190,628,907.07, while cash outflow was $272,099,980.73, resulting in a net cash flow from investment activities of -$81,471,073.66[36] - Cash flow from financing activities showed an inflow of $59,150,000.00, down from $70,000,000.00 in the previous period, with a net cash flow of $57,369,369.73[38] - The ending balance of cash and cash equivalents was $459,963,445.48, a decrease from $488,928,451.07 at the beginning of the period[38] Operational Metrics - The company's international business grew by 67% compared to the same period last year, contributing to overall revenue growth[11] - Research and development expenses for Q1 2022 were ¥10,600,202.65, down from ¥15,604,437.09 in Q1 2021, a decrease of 32.1%[28] - The company reported a financial expense of ¥1,920,268.93 in Q1 2022, compared to a financial income of ¥3,683,285.03 in Q1 2021[28] - The company reported cash inflow from other investment activities of $190,628,907.07, significantly higher than $961,789.25 in the previous period[36] Changes in Accounts - Accounts receivable increased significantly to CNY 199.96 million from CNY 66.24 million, marking an increase of approximately 201.06%[18] - Short-term borrowings rose to CNY 103.15 million from CNY 65.07 million, reflecting an increase of about 58.66%[22] - The company's accounts payable decreased to CNY 181.55 million from CNY 200.48 million, a decline of approximately 9.43%[22] - The company reported a significant increase in contract liabilities to CNY 60.75 million from CNY 23.23 million, representing a growth of approximately 161.56%[22] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[16] - Non-recurring gains and losses included government subsidies of RMB 596,552.50 and other income of RMB 68,250.00[11] - Cash outflow for employee compensation was $45,710,000.12, up from $33,164,389.91, reflecting increased payroll expenses[36] - Cash outflow for other operating activities was $23,356,493.52, compared to $18,300,261.01, indicating higher operational costs[36] - The impact of exchange rate changes on cash and cash equivalents was -$2,535,464.84, contrasting with a positive impact of $2,278,316.32 in the previous period[38]